Cabaletta Bio, INC 10-Q quarterly reports

Cabaletta Bio reports increased R&D expenses and continued net losses, highlighting substantial doubt about its ability to continue as a going concern and the need for significant future financing.

Cabaletta Bio, Inc. reported its first quarter 2026 financial results, detailing increased research and development expenses and a net loss, while highlighting progress in its clinical-stage pipeline for autoimmune diseases.

Cabaletta Bio reported increased net losses and significant R&D expenses in Q3 2025, while advancing multiple rese-cel clinical trials and securing additional financing to extend its cash runway into H2 2026.

Cabaletta Bio reports increased R&D spend and net losses, fueled by promising clinical data for its lead CAR T candidate rese-cel and a significant capital raise.

Cabaletta Bio reports its financial results for the first quarter of 2025, highlighting progress in its clinical programs and strategic initiatives.

Cabaletta Bio's Q3 2024 report details financial results, clinical trial progress, and updates on manufacturing and collaborations.

Cabaletta Bio, a clinical-stage biotechnology company, released its second quarter 2024 financial results and provided an update on its clinical programs, including the RESET trials for CABA-201.

Cabaletta Bio, a clinical-stage biotechnology company, released its first quarter 2024 financial results, highlighting ongoing clinical trials and strategic collaborations.